Power of selective genotyping in genome-wide association studies of quantitative traits by Xing, Chao & Xing, Guan
BMC Proceedings
Proceedings
Power of selective genotyping in genome-wide association studies
of quantitative traits
Chao Xing*
1,2 and Guan Xing
3
Addresses:
1Department of Clinical Sciences, University of Texas Southwestern Medical Center, Dallas, Texas 75390, USA,
2McDermott Center of
Human Growth and Development, University of Texas Southwestern Medical Center, Dallas, Texas 75390, USA and
3Bristol-Myers Squibb
Company, 311 Pennington-Rocky Hill Road, Pennington, New Jersey 08534, USA
E-mail: Chao Xing* - chao.xing@utsouthwestern.edu; Guan Xing - guan.xing@bms.com
*Corresponding author
from Genetic Analysis Workshop 16
St Louis, MO, USA 17-20 September 2009
Published: 15 December 2009
BMC Proceedings 2009, 3(Suppl 7):S23 doi: 10.1186/1753-6561-3-S7-S23
This article is available from: http://www.biomedcentral.com/1753-6561/3/S7/S23
© 2009 Xing and Xing; licensee BioMed Central Ltd.
This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0),
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Abstract
The selective genotyping approach in quantitative genetics means genotyping only individuals with
extreme phenotypes. This approach is considered an efficient way to perform gene mapping, and
can be applied in both linkage and association studies. Selective genotyping in association mapping
of quantitative trait loci was proposed to increase the power of detecting rare alleles of large effect.
However, using this approach, only common variants have been detected. Studies on selective
genotyping have been limited to single-locus scenarios. In this study we aim to investigate the
power of selective genotyping in a genome-wide association study scenario, and we specifically
study the impact of minor allele frequency of variants on the power of this approach. We use the
Genetic Analysis Workshop 16 rheumatoid arthritis whole-genome data from the North American
Rheumatoid Arthritis Consortium. Two quantitative traits, anti-cyclic citrullinated peptide and
rheumatoid factor immunoglobulin M, and one binary trait, rheumatoid arthritis affection status,
are used in the analysis. The power of selective genotyping is explored as a function of three
parameters: sampling proportion, minor allele frequency of single-nucleotide polymorphism, and
test level. The results show that the selective genotyping approach is more efficient in detecting
common variants than detecting rare variants, and it is efficient only when the level of declaring
significance is not stringent. In summary, the selective genotyping approach is most suitable for
detecting common variants in candidate gene-based studies.
Background
The extreme sampling strategy in quantitative genetics
is termed selective genotyping [1], involving phenotyp-
ing a large population of individuals, but genotyping
only those individuals whose phenotypes deviate
substantially from the mean. This approach was first
introduced in a linkage context and was readily
adopted in association analysis by treating the upper
and lower subpopulations as case and control groups,
respectively.
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Open AccessThis selective genotyping approach was shown to be
efficient in association mapping of quantitative trait loci
(QTLs) in a statistical framework [2,3]. Since then, there
have been several theoretical studies proposing alter-
native test statistics [4,5] or alternative sampling
procedures [6], and extending this approach to haplo-
type analysis [7]. It is important to note that the selective
genotyping approach was initially proposed to increase
the power of detecting rare alleles with large effect at
QTLs, but all the theoretical work cited assumed an
unrealistic assumption of a large sample size even in the
subpopulation of each extreme. The selective genotyping
design has been applied to identify association between
quantitative traits and genetic markers. For example, it
was applied in studying genetic association of intelli-
gence scores [8], attention-deficit hyperactivity disorder
[9], and body mass index [10]. It is worth noting that in
all of the studies mentioned previously that had positive
results, the alleles of interest were common (minor allele
frequency, or MAF > 0.20).
Both theoretical and applied studies to date have focused
on limited number of loci in a candidate gene study
scenario, and therefore their test levels were set high.
They made no comparison between common and rare
variants in a realistic situation in terms of sample size. In
this study we investigated the empirical power of
selective genotyping using the Genetic Analysis Work-
shop 16 (GAW16) rheumatoid arthritis (RA) genome-
wide association study (GWAS) data from the North
American Rheumatoid Arthritis Consortium (NARAC).
The genome-wide data provided us an opportunity to
investigate the power at different test levels and a full
spectrum of allele frequency.
Methods
The NARAC data consists of 868 cases and 1,194
controls. The samples were genotyped using the Illumina
Infinium HumanHap550 chip, and in the current study
we focused on 531,689 single-nucleotide polymorph-
isms (SNPs) across the autosomal genome. The data
were filtered through genotype call rate (>90% com-
pleteness) and the Hardy-Weinberg equilibrium test
(p-value > 0.001), and 522,587 SNPs were retained.
Note that we did not filter the data through a MAF
criterion because the MAF was a primary variable we
were investigating. To control for population stratifica-
tion, we calculated the first two principal components,
denoted PC1 and PC2, of 1,344 ancestry-informative
SNPs [11] and adjusted for them together with sex in the
subsequent association analysis. Because all individuals
were genotyped, we chose a proportion of the whole
sample to mimic the selective genotyping procedure.
Given a quantitative trait, the upper N
th, N Œ {10, 20,
30, 40, 50, 60, 70, 80, 90, 100}, percentiles of cases, and,
correspondingly, a random N percent of controls were
selected as a study dataset, i.e., there were 10 datasets
generated in total. All subjects were included when N =
100. A total of three RA-related traits, including a binary
variable of RA affection status and two quantitative
phenotypes (anti-cyclic citrullinated peptide, or anti-
CCP and immunoglobulin M, or IgM) measured only in
cases were used in the analyses.
The statistical testing procedure included three steps.
First, we tested association between affection status and
genotype using both cases and controls by a logistic
regression model, which yielded a statistic T1. Second,
we tested association between a quantitative trait and
genotype in the selected cases by a linear regression
model, which yielded a statistic T2.B e c a u s et h e
distribution of a quantitative trait in the selected cases
might not be normally distributed, the Box-Cox power
transformation [12] was always performed in the linear
regression. Covariates PC1, PC2, and sex were adjusted
in both tests. Third, because T1 and T2 were independent
under the null hypothesis of no association between the
traits and genotype, we employed the Fisher’sm e t h o d
of combining p-values [13] to form a statistic
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= ∏ log ~ χ ,w h e r eP(Ti) denotes the
p-value corresponding to the test statistic Ti.W e
concentrated on results based on T3 in the subsequent
analysis because it was shown to be more powerful than
the other two [2].
To investigate the empirical power of selective genotyp-
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p-value < 0.05 under control of the false-discovery rate
(FDR) [14] when using the whole sample. Setting the
results using the whole sample as the gold standard, we
defined relative power as, at a certain test level a,t h e
total number of significant SNPs using a subset of data
(N < 100) divided by the total number of significant
SNPs using the whole data (N = 100). We studied the
relative power as a function of three sets of parameters:
the sampling proportion N%, N Œ {10, 20, 30, 40, 50,
60, 70, 80, 90, 100}, the test level a =5 . 0×1 0
0, O Œ {-2,
-3, -4, -5, -6, -7, -8}, and the SNP MAF stratified by p,
p Œ {0.05, 0.10, 0.20, 0.30, 0.40}. All analyses were
performed using the software PLINK [15] and R [16].
Results
We first performed a genome scan using the whole
sample, and were able to detect loci confirmed to be
associated with RA such as the major histocompatibility
complex on chromosome 6, PTPN22 on chromosome 1,
and TRAF1-C5 on chromosome 9 (data not shown),
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attain a p-value < 0.05 under FDR control, the nominal
p-values for anti-CCP and IgM were 2.35 × 10
-6 and
2.34 × 10
-6, respectively. There were 336 SNPs for anti-
CCP and 337 SNPs for IgM that met these criteria. Their
distributions across chromosomes and allele frequency
categories are summarized in Tables 1 and 2. There were
no SNPs with a MAF < 0.01 that met the criteria, and
therefore the lowest threshold of MAF to stratify SNPs
was 0.05.
The power of selective genotyping strategy depended on
the test levels. This approach was efficient only when the
level of declaring significance was not stringent. To
achieve a relative power greater than 0.8, less than 30%
of the sample needed to be genotyped when the test level
was equal to or greater than 5 × 10
-3; however, more
than 50% of the sample needed to be genotyped at the
t e s tl e v e lo f5×1 0
-5; when the test level was equal to or
l e s st h a n5×1 0
-6, the power decreased linearly with the
sample size (Figure 1). Stratifying each line in Figure 1
by the MAF, we found the efficiency of selective
genotyping increased as the MAF increased regardless
of test levels (Figure 2). In other words, this approach
was most efficient in detecting common variants. We
observed similar results for both traits, and only
presented those for anti-CCP.
Discussion
Selecting individuals with extreme phenotypes increases
the narrow sense of heritability of the trait in the sample
at the cost of decreasing sample size. Therefore, there is a
trade-off between these two factors to achieve a certain
level of statistical power. This approach is more efficient
in detecting common variants than detecting rare
variants because the effective sample size (the number
of variants in a sample) decreases more rapidly for rare
variants as we decrease the sampling proportion.
Selective genotyping is commonly practiced by genotyp-
ing individuals with extreme phenotypes at both upper
and lower extremes; however, in the current study we
only selected those at the upper extremes in cases and
then made random selection in controls. This study
design was based on the trait characteristics, not
constraints of the data available. Both anti-CCP and
IgM are usually present only in cases, i.e., both
quantitative traits are zero in unaffected persons. There-
fore, the study population approximates a selected
sample plus a random sample from the general popula-
tion, similar to the design proposed by Slatkin [2].
Conclusion
The selective genotyping approach is more efficient in
detecting common variants than detecting rare variants
even though it was initially proposed to detect the latter
[2]. This approach is efficient only when the level of
declaring significance is not stringent; therefore, it
should not be employed in a GWAS, though it can be
used in a replication study to confirm findings of the
G W A S .I ns u m m a r y ,t h es e l e c t i v eg e n o t y p i n ga p p r o a c hi s
most suitable for detecting common variants in candi-
date gene-based studies.
Table 1: Genomic distribution of SNPs attaining a p-value < 0.05
under control of the false discovery rate using the whole sample
Chromosome anti-CCP IgM
12 3
21 0
33 1
53 2
6 313 318
97 7
12 1 0
14 0 1
15 1 0
16 3 3
17 2 1
18 0 1
Total 336 337
Table 2: Allele frequency distribution of SNPs attaining a p-value<
0.05 under control of the false discovery rate using the whole
sample
MAF anti-CCP IgM
0.40 ~ 0.50 67 70
0.30 ~ 0.40 79 78
0.20 ~ 0.30 51 52
0.10 ~ 0.20 101 100
0.05 ~ 0.10 35 33
<0 . 0 5 3 4
Total 336 337
Figure 1
Relative power of selective genotyping at different
test levels for trait anti-CCP.
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anti-CCP: Anti-cyclic citrullinated peptide (anti-CCP);
FDR: False-discovery rate; GAW16: Genetic Analysis
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NARAC: North American Rheumatoid Arthritis Consor-
tium; QTLs: Quantitative trait loci; RA: Rheumatoid
arthritis; SNP: Single-nucleotide polymorphism.
Figure 2
Relative power of selective genotyping at different test levels stratified by the minor allele frequency for trait
anti-CCP.
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